Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
4D Molecular Therapeutics Inc (FDMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: FDMT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 43.17% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 138.44M USD | Price to earnings Ratio - | 1Y Target Price 33.82 |
Price to earnings Ratio - | 1Y Target Price 33.82 | ||
Volume (30-day avg) 723060 | Beta 2.82 | 52 Weeks Range 2.87 - 29.27 | Updated Date 04/2/2025 |
52 Weeks Range 2.87 - 29.27 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.98 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5611700% |
Management Effectiveness
Return on Assets (TTM) -26.08% | Return on Equity (TTM) -39.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -261826804 | Price to Sales(TTM) 3741.73 |
Enterprise Value -261826804 | Price to Sales(TTM) 3741.73 | ||
Enterprise Value to Revenue 8.57 | Enterprise Value to EBITDA -3.55 | Shares Outstanding 46302400 | Shares Floating 34309158 |
Shares Outstanding 46302400 | Shares Floating 34309158 | ||
Percent Insiders 3.89 | Percent Institutions 103.16 |
Analyst Ratings
Rating 4.08 | Target Price 45.4 | Buy 5 | Strong Buy 5 |
Buy 5 | Strong Buy 5 | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
4D Molecular Therapeutics Inc
Company Overview
History and Background
4D Molecular Therapeutics (4DMT) was founded in 2013. It's a clinical-stage biotherapeutics company focused on developing gene therapies using its Therapeutic Vector Evolution platform.
Core Business Areas
- Gene Therapy Development: Develops adeno-associated virus (AAV) gene therapies for various diseases, using its evolved vectors to improve delivery and efficacy.
Leadership and Structure
David Kirn, M.D. is the CEO. The company has a typical biotech organizational structure with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- 4D-150 (wet AMD): A gene therapy product candidate for wet age-related macular degeneration (wet AMD), aims for one-time durable treatment. Competing with Regeneron's Eylea, Roche's Vabysmo, and Novartis' Beovu. Market share N/A. No current revenue.
- 4D-710 (cystic fibrosis): A gene therapy product candidate for cystic fibrosis (CF). Competing with Vertex's CFTR modulators. Market share N/A. No current revenue.
Market Dynamics
Industry Overview
The gene therapy market is growing rapidly, driven by advances in vector technology and increasing regulatory approvals. The market is highly competitive with large pharmaceutical companies and smaller biotech firms.
Positioning
4DMT is positioned as a leader in AAV gene therapy vector design, with a focus on improving delivery and targeting. Its Therapeutic Vector Evolution platform gives them competitive edge to create best in class therapies.
Total Addressable Market (TAM)
The total addressable market for gene therapy is estimated to be in the tens of billions of dollars. 4DMT aims to capture significant market share through its differentiated vector technology and pipeline of product candidates.
Upturn SWOT Analysis
Strengths
- Proprietary Therapeutic Vector Evolution platform
- Strong preclinical and clinical data
- Experienced management team
- Focus on targeted gene therapy
Weaknesses
- Limited product pipeline
- High R&D expenses
- Dependence on clinical trial success
- Reliance on vector manufacturability at scale
Opportunities
- Expanding pipeline through internal development and partnerships
- Securing regulatory approvals for product candidates
- Out-licensing or selling products
- Expanding into new therapeutic areas
Threats
- Clinical trial failures
- Competition from other gene therapy companies
- Regulatory hurdles
- Manufacturing challenges
- Adverse events associated with gene therapy
Competitors and Market Share
Key Competitors
- VIR
- BMY
- VRTX
Competitive Landscape
4DMT's vector technology provides a competitive advantage. However, it competes with larger, more established pharmaceutical companies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is linked to clinical trial progression, partnership deals, and regulatory milestones.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and market acceptance of its gene therapy products. Analyst projections vary.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead product candidates and expanding its pipeline through internal development and partnerships.
Summary
4D Molecular Therapeutics is a clinical-stage biotech firm with a focus on gene therapies. Its proprietary vector evolution platform provides a competitive edge, and successful clinical trials are critical for its long-term success. The company needs to advance key clinical programs and continue to find ways to fund its expensive pipeline. Competition and regulatory hurdles remain significant risks.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
VIR
Vir Biotechnology Inc
VIR
Vir Biotechnology Inc
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- 4D Molecular Therapeutics website
- SEC filings
- Analyst reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and risk tolerance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 4D Molecular Therapeutics Inc
Exchange NASDAQ | Headquaters Emeryville, CA, United States | ||
IPO Launch date 2020-12-11 | Co-Founder, CEO & Director Dr. David H. Kirn M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 227 | |
Full time employees 227 | |||
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. It also develops 4D-175 for geographic atrophy in preclinical with open IND; 4D-725 for alpha-1 anti-trypsin deficiency lung disease in preclinical; and 4D-310 for Fabry disease, which is in Phase 1 clinical trials. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; uniQure biopharma B.V; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.